Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 264-272

  Yeo, Dannel ^a   Huynh, Nhi ^a   Beutler, John A ^b   Christophi, Christopher ^a   Shulkes, Arthur ^a   Baldwin, Graham S ^a   Nikfarjam, Mehrdad ^a   He, Hong ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Glaucarubinone; P21 activated kinases; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GLAUCARUBINONE; NATURAL PRODUCT; P21 ACTIVATED KINASE; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 4; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEOXYCYTIDINE; GLAUCARUBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL GROWTH; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

MUS; SIMAROUBA GLAUCA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; ENZYME ACTIVATION; GLAUCARUBIN; HUMANS; MICE; MICE, NUDE; P21-ACTIVATED KINASES; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896136615     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.001     Document Type: Article

References (28)

1. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
2. Yeo T.P., Hruban R.H., Leach S.D., Wilentz R.E., Sohn T.A., Kern S.E., Iacobuzio-Donahue C.A., Maitra A., Goggins M., Canto M.I., Abrams R.A., Laheru D., Jaffee E.M., Hidalgo M., Yeo C.J. Pancreatic cancer. Curr. Probl. Cancer 2002, 26:176-275.
3. Allison D.C., Piantadosi S., Hruban R.H., Dooley W.C., Fishman E.K., Yeo C.J., Lillemoe K.D., Pitt H.A., Lin P., Cameron J.L. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J. Surg. Oncol. 1998, 67:151-159.
4. Kayahara M., Nagakawa T., Ueno K., Ohta T., Takeda T., Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993, 72:2118-2123.
5. Castellanos E., Berlin J., Cardin D.B. Current treatment options for pancreatic carcinoma. Curr. Oncol. Rep. 2011, 13:195-205.
6. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., Morsberger L.A., Latimer C., McLaren S., Lin M.L., McBride D.J., Varela I., Nik-Zainal S.A., Leroy C., Jia M., Menzies A., Butler A.P., Teague J.W., Griffin C.A., Burton J., Swerdlow H., Quail M.A., Stratton M.R., Iacobuzio-Donahue C., Futreal P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
7. Molli P.R., Li D.Q., Murray B.W., Rayala S.K., Kumar R. PAK signaling in oncogenesis. Oncogene 2009, 28:2545-2555.
8. Chen S., Auletta T., Dovirak O., Hutter C., Kuntz K., El-ftesi S., Kendall J., Han H., Von Hoff D.D., Ashfaq R., Maitra A., Iacobuzio-Donahue C.A., Hruban R.H., Lucito R. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol. Ther. 2008, 7:1793-1802.
9. Kimmelman A.C., Hezel A.F., Aguirre A.J., Zheng H., Paik J.H., Ying H., Chu G.C., Zhang J.X., Sahin E., Yeo G., Ponugoti A., Nabioullin R., Deroo S., Yang S., Wang X., McGrath J.P., Protopopova M., Ivanova E., Zhang J., Feng B., Tsao M.S., Redston M., Protopopov A., Xiao Y., Futreal P.A., Hahn W.C., Klimstra D.S., Chin L., DePinho R.A. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc. Natl. Acad. Sci. USA 2008, 105:19372-19377.
10. Chauhan S.C., Ebeling M.C., Maher D.M., Koch M.D., Watanabe A., Aburatani H., Lio Y., Jaggi M. MUC13 mucin augments pancreatic tumorigenesis. Mol. Cancer Ther. 2012, 11:24-33.
11. Wang Z., Oh E., Clapp D.W., Chernoff J., Thurmond D.C. Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo. J. Biol. Chem. 2011, 286:41359-41367.
12. Monjour L., Rouquier F., Alfred C., Polonsky J. Therapeutic trials of experimental murine malaria with the quassinoid, glaucarubinone. C. R. Acad. Sci. 1987, 304:129-132.
13. Valeriote F.A., Corbett T.H., Grieco P.A., Moher E.D., Collins J.L., Fleck T.J. Anticancer activity of glaucarubinone analogues. Oncol. Res. 1998, 10:201-208.
14. Fiaschetti G., Grotzer M.A., Shalaby T., Castelletti D., Arcaro A. Quassinoids: from traditional drugs to new cancer therapeutics. Curr. Med. Chem. 2011, 18:316-328.
15. Beutler J.A., Kang M.I., Robert F., Clement J.A., Pelletier J., Colburn N.H., McKee T.C., Goncharova E., McMahon J.B., Henrich C.J. Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition. J. Nat. Prod. 2009, 72:503-506.
16. Maruta H. Herbal therapeutics that block the oncogenic kinase PAK1: a practical approach towards PAK1-dependent diseases and longevity. Phytother. Res.: PTR 2013.
17. Sicard A., Semblat J.P., Doerig C., Hamelin R., Moniatte M., Dorin-Semblat D., Spicer J.A., Srivastava A., Retzlaff S., Heussler V., Waters A.P., Doerig C. Activation of a PAK-MEK signalling pathway in malaria parasite-infected erythrocytes. Cell. Microbiol. 2011, 13:836-845.
18. Yanase S., Luo Y., Maruta H. PAK1-deficiency/down-regulation reduces brood size, activates HSP16.2 gene and extends lifespan in Caenorhabditis elegans. Drug Discov. Therap. 2013, 7:29-35.
19. Huynh N., Liu K.H., Baldwin G.S., He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim. Biophys. Acta 1803, 2010:1106-1113.
20. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
21. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
22. He H., Hirokawa Y., Gazit A., Yamashita Y., Mano H., Kawakami Y., Kawakami, Hsieh C.Y., Kung H.J., Lessene G., Baell J., Levitzki A., Maruta H. The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol. Ther. 2004, 3:96-101.
23. Callow M.G., Clairvoyant F., Zhu S., Schryver B., Whyte D.B., Bischoff J.R., Jallal B., Smeal T. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J. Biol. Chem. 2002, 277:550-558.
24. Tabusa H., Brooks T., Massey A.J. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol. Cancer Res.: MCR 2013, 11:109-121.
25. Michl P., Gress T.M. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013, 62:317-326.
26. Sun C., Ansari D., Andersson R., Wu D.Q. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?. World J. Gastroenterol.: WJG 2012, 18:4944-4958.
27. Vincent J., Hochhalter A.K., Broglio K., Avots-Avotins A.E. Survey respondents planning to have screening colonoscopy report unique barriers. Permanente J. 2011, 15:4-11.
28. Vincent F., Duncton M.A. TRPV4 agonists and antagonists. Curr. Top. Med. Chem. 2011, 11:2216-2226.